Baird Maintains Castle Biosciences(CSTL.US) With Buy Rating, Raises Target Price to $39

贝雅维持Castle Biosciences(CSTL.US)买入评级，上调目标价至39美元

moomoo资讯 · 2024/11/05 20:35 · 评级/大行评级

Baird analyst Catherine Ramsey Schulte maintains $Castle Biosciences (CSTL.US)$ with a buy rating, and adjusts the target price from $37 to $39.

According to TipRanks data, the analyst has a success rate of 54.5% and a total average return of 12.4% over the past year.

AnalystRecentRatingAutoNews_77704548536000_20241105_0569c2fe1d7f0c3d05c0808d3ab82dadef3aeb71_1730809870243101_mm_en

Furthermore, according to the comprehensive report, the opinions of $Castle Biosciences (CSTL.US)$'s main analysts recently are as follows:

Castle Biosciences reported a robust third quarter, with revenues meeting expectations and showing promising operational expenditure leverage. The company experienced overall volume growth, although dermatology volumes fell short of estimates because of seasonal factors. Meanwhile, the TissueCypher product continued to display significant momentum.
The company's continuous expansion of volumes for its variety of tests, including growth seen in IDgenetix and TissueCypher, has been a contributing factor to the robust quarterly results and the elevated revenue forecasts.

Note:

TipRanks, an independent third party, provides analysis data from financial analysts and calculates the Average Returns and Success Rates of the analysts' recommendations. The information presented is not an investment recommendation and is intended for informational purposes only.

Success rate is the number of the analyst's successful ratings, divided by his/her total number of ratings over the past year. A successful rating is one based on if TipRanks' virtual portfolio earned a positive return from the stock. Total average return is the average rate of return that the TipRanks' virtual portfolio has earned over the past year. These portfolios are established based on the analyst's preliminary rating and are adjusted according to the changes in the rating.

TipRanks provides a ranking of each analyst up to 5 stars, which is representative of all recommendations from the analyst. An analyst's past performance is evaluated on a scale of 1 to 5 stars, with more stars indicating better performance. The star level is determined by his/her total success rate and average return.

贝雅分析师Catherine Ramsey Schulte维持$Castle Biosciences (CSTL.US)$买入评级，并将目标价从37美元上调至39美元。

根据TipRanks数据显示，该分析师近一年总胜率为54.5%，总平均回报率为12.4%。

AnalystRecentRatingAutoNews_77704548536000_20241105_0569c2fe1d7f0c3d05c0808d3ab82dadef3aeb71_1730809870243101_mm_sc

此外，综合报道，$Castle Biosciences (CSTL.US)$近期主要分析师观点如下：

castle biosciences报告第三季度强劲，营业收入符合预期，并显示了有前景的营运支出潜力。公司整体经历了成交量增长，尽管由于季节因素，皮肤病学成交量未达到预期。同时，TissueCypher产品持续显示出显著的势头。
公司持续扩大各种测试的成交量，包括IDgenetix和TissueCypher中的增长，已成为强劲季度业绩和提升的营业收入预测的原因之一。

提示:

TipRanks为独立第三方，提供金融分析师的分析数据，并计算分析师推荐的平均回报率和胜率。提供的信息并非投资建议，仅供参考。本文不对评级数据和报告的完整性与准确性做出认可、声明或保证。

TipRanks提供每位分析师的星级，分析师星级代表分析师所有推荐的过往表现，通过分析师的总胜率和平均回报率综合计算得出，星星越多，则该分析师过往表现越优异，最高为5颗星。

分析师总胜率为近一年分析师的评级成功次数占总评级次数的比率。评级的成功与否，取决于TipRanks的虚拟投资组合是否从该股票中产生正回报。

总平均回报率为基于分析师的初始评级创建虚拟投资组合，并根据评级变化对组合进行调整，在近一年中该投资组合所获得的回报率。

声明：本内容仅用作提供资讯及教育之目的，不构成对任何特定投资或投资策略的推荐或认可。更多信息

Baird Maintains Castle Biosciences(CSTL.US) With Buy Rating, Raises Target Price to $39

Baird Maintains Castle Biosciences(CSTL.US) With Buy Rating, Raises Target Price to $39

风险及免责提示

声明